Actemra 200 mg/10 ML 1 vial

Actemra (tocilizumab) 200 mg/10 mL (20 mg/mL) is a prescription, concentrated intravenous (IV) infusion medication used to treat conditions like moderate-to-severe active rheumatoid arthritis, systemic sclerosis-associated interstitial lung disease, and juvenile idiopathic arthritis. It acts as an immunosuppressant by targeting interleukin-6 (IL-6) receptors.

Key Details for Actemra 200 mg/10 mL Vial:

Indication: Primarily used for adult RA patients after other treatments (DMARDs) have failed.
Administration: It must be diluted by a healthcare professional and given as a slow intravenous infusion.
Dosage: The dose is based on body weight, requiring consistent monitoring by a doctor.
Safety Information: Actemra may lead to serious allergic reactions, an increased risk of infections, or malignancies.
Storage: Vials must be stored in a refrigerator (2°C – 8°C or 36°F – 46°F) and not frozen.
Availability: Available through authorized specialty distributors.

Medical Uses
Actemra is an interleukin-6 (IL-6) receptor antagonist that helps reduce inflammation. It is commonly prescribed for:

Rheumatoid Arthritis (RA): For adults with moderate to severe active RA.
Juvenile Idiopathic Arthritis: Used for both systemic (sJIA) and polyarticular (pJIA) types in children over 2 years old.
COVID-19: Indicated for certain hospitalised adults receiving corticosteroids and requiring oxygen.
Other conditions: Including Giant Cell Arteritis (GCA) and Cytokine Release Syndrome (CRS).

Administration & Dosage

Method: Must be diluted by a healthcare professional and administered as a 60-minute intravenous drip.
Frequency: For RA, it is typically given once every 4 weeks.
Dosage: Often based on patient weight (e.g., starting at 4 mg/kg and potentially increasing to 8 mg/kg).